The fragility fracture is the widest spread of the bone diseases, in elderly. It particularly affects the vertebrae, the femur, the proximal humerus, the distal radius, the pelvis, thus preventing the patient's free movement. The most debilitating of all these fractures is the fragility fracture of the pelvis. This type of fracture raises supplementary problems compared to the other fractures due to the difficulties of diagnosis, surgical approach and to the longer recovery period. Choosing the right treatment for FFP is difficult due to health and comorbidities in elderly patients. Both conservative and surgical therapy involve equally large risks: prolonged immobilization or surgical risks. Therefore, pharmacological therapy is an alternative to surgery. Bisphosphonates prove their utility in the fracture-healing outcome, but the influence of calcium and vitamin D were overlooked. The aim of our study was to evaluate the role of calcium and vitamin D in the healing process of patients with pelvic fragility fracture in osteoporotic patients with and without calcium and vitamin D supplementation. Our study shows that calcium and vitamin D exert a positive influence on the healing process of the fragility fractures and strongly emphasizes the need to educate patients to comply with the prescription to supplement calcium and vitamin D in order to improve fracture healing and prevent additional fractures.

Keywords: osteoporosis, fragility fracture, pelvis, calcium, vitamin D

Nowadays osteoporosis is one of the most common bone diseases encountered in older population. The major consequence of osteoporosis is the risk of fractures called fragility fractures (FF). Fragility fractures are serious medical problems, both due to the high costs of treatment and the severe decrease in the patient's quality of life. Fragility fracture occurs when structural changes suffered by the bone affect its biomechanical characteristics such as resistance to compression and torsional forces. The World Health Organization (WHO) defines a fragility fracture as one caused by a trauma that would be insufficient to injure bone if the bone substance were normal [1]. The most common fragility fractures are located in the vertebrae, femur, proximal humerus, distal radius. A particular case is the fragility fracture of the pelvis (FFP) whose incidence has increased lately. This type of fracture raises supplementary problems compared to the other fractures due to the difficulties of diagnosis, surgical approach and to the longer recovery period. As a general rule, literature recommends conservative treatment as long as it leads to pain relief, allows mobilization and no displacements is noticed. Surgery is recommended when pain prevent patient to mobilize or when fractures are unstable [2, 3]. Alternatively, to surgery, pharmacological therapy can reduce the risk of fracture by 30% to 40% by using vitamin D, Ca supplementation, anti-osteoporotic (bisphosphonates, denosumab, raloxifene) or anabolic drugs (teriparatide) for bone repair [4]. The healing process of a fracture involves the participation of endogenous factors as well as exogenous factors such as vitamin D and calcium. Osteoporosis is characterized by increased calcium level but it is generated by the process of the systemic bone loss. More than 50% of the hypercalcemia cases, found in women, are associated with osteoporosis. In osteoporosis, detected calcium levels were greater than 2.56 mmol/L, the reference range being 2.15-2.55 mmol/L [5]. In the case of osteoporotic bone, the healing process is much slower [6] and the calcium and vitamin D deficiency has more severe consequences on systemic bone mineralization. The risk is even higher in the case of fractured osteoporotic bone when the increased calcium requirement for fracture-callus mineralization is provided by systemic bone resorption. In other words, post-traumatic bone loss leads to exacerbation of osteoporosis, increasing the risk of secondary fracture, 3 times [7]. The literature indicates that the subsequent bone loss after a fracture is estimated between 2-15% of the bone mass [8-12]. Therefore, the need for the use of bone anti-resorption agents associated with calcium and vitamin D supplementation appears obvious [7]. The aim of our study was to evaluate the role of calcium and vitamin D in the healing process of patients with pelvic fragility fracture in osteoporotic patients with and without calcium and vitamin D supplementation. Serum calcium and vitamin D levels

* email: ovidiu_alexa@yahoo.com; pdsirbu@yahoo.com; cfilip2000@yahoo.com. All authors contributed equally to this paper.

http://www.revistadechimie.ro REV.CHIM.(Bucharest) 70  No. 10  2019
were monitored during hospitalizations, 14 days and one month after discharge. The obtained data were correlated with the level of pain, its decrease being considered a sign of healing. The data obtained show that the healing process of the osteoporotic bone is improved when combining anti-osteoporotic medication with calcium and vitamin D supplementation. This study indicates the need to educate patients in order to comply with the prescription of treatment and to supplement calcium and vitamin D in order to improve fracture healing and prevent secondary fractures.

**Experimental part**

The study was realized on patients who experienced pelvic fracture, admitted between January 2015 and January 2019 at the St. Spiridon Emergency Hospital, Iași, Romania. The inclusion criteria for the patients in the study were: osteoporotic patients aged 60 years and older. Exclusions criteria were: patients with pelvic injuries from high energy trauma or oncological bone diseases, patients not diagnosed with osteoporosis before fracture and osteoporotic patients with previous fractures in history. The fractures had been confirmed by X-ray or computer tomography. Clinical parameters as age, sex, comorbidities (diabetes, heart failure, renal failure etc), bone mineral density (BMD), osteoporosis therapy, alcohol/nicotine abuse and menopausal hormone therapy were recorded. Informed consent from all patients included in this study was obtained. The current research has been conducted in accordance to the ethical principles set out by the Helsinki Declaration and by the Ethical Committee from our university. Patients were divided in 2 groups: Group I-patients receiving osteoporotic treatment (bisphosphonates) before fracture and supplemented with calcium and vitamin D, Group II- patients receiving osteoporotic treatment (bisphosphonates) before fracture but not supplemented with calcium and vitamin D by voluntarily not complying with the prescription or ceasing osteoporotic therapy, due to negligence, or other reasons. Group I contains 22 patients aged 63-85 years (16 women, 6 males). Group II contains 31 patients aged between 60-81 years (23 women, 8 males). Patients in both groups was conservatively treated and received pain medication. Patients were monitored for a short-term follow-up during hospitalization, in our clinic or in specialized recovery department, for 14 days and 1 month after hospital discharge. During hospitalization we monitored the time required to reduce pain by using the visual analog scale or VAS [4]. Relieving pain was considered a favorable sign in the healing process. Patients with constant or increased pain were re-evaluated by X-ray to identify fracture displacement or other causes and were excluded from the study. At admission, routine analyses including serum calcium levels were determined for all patients in hospital laboratory. Vitamin D was also determined for patients in the biochemistry department by using a 25-OH vitamin D DRG Elisa kit 5396 for manual use. The one-month follow-up was done either by patient re-assessment or by interviewing patients by telephone. At one month after discharge, 15(67%) patients from group I and 19 (61%) from group II, came back for re-assessment. They were investigated for X-ray radiography, serum calcium and vitamin D levels.

**Results and discussions**

Fractures are widely encountered in osteoporotic patients. In group I, the appearance of FFP, in patients undergoing osteoporotic therapy and calcium and vitamin D supplementation, may be caused by an older age in this group. The administration of bisphosphonates is effective in preventing fractures in 40% of osteoporotic patients over 70 years (reported data for the femur), but does not show similar improvements over 80 years of age [13, 14]. In group II, the fracture is caused by non-complying to the therapy; the literature indicates an FF incidence of 30%-50% (including hip, shoulder, humerus, pelvis) in patients who do not follow the treatment as prescribed [15]. In the case of any fracture including FFP, pain reduction is an indication of the favorable evolution of the healing process. Pain can be assessed with a VAS score where interpretation after Jensen [16] is realized on a scale of 10 cm (100 mm) as follows: no pain (0-4 mm), mild pain (5-44 mm), moderate pain (45-74 mm) and severe pain (75-100 mm). The influence of calcium in the healing process of the osteoporotic fracture is assessed by correlating its serum profile with pain reduction, is shown in figures 1 (a) and respectively figure 1 (b).

For group I-in osteoporotic patients previously supplied with calcium and vitamin D, the pain decreases and reach the mild range around the 8th day after admission. For group II-in osteoporotic patients not supplied previously with calcium and vitamin D, the pain decreases and reach the mild range around the 10th day. Serum calcium levels decrease after fracture, in both groups. The decrease is moderate in group I, severe in group II, and statistically significant between the two groups (p<0.005). This behavior was noticed as an effect to the initiation of the remodeling process [8]. Calcium is essential for the callus mineralization. The calcium needed for this process is obtained on account of systemic bone resorption in favor of fracture healing. Therefore, the loss of systemic bone mass in the case of osteoporosis is much accentuated in the context of a calcium deficiency. As shown in Figure 1 (b), the low levels of calcium coincide with a delay of the pain reduction time which, although insignificant, indicates a longer time span for the fracture healing. Therefore, calcium supplementation in FFP becomes necessary not only to support the fracture healing but also to avoid additional fractures. Vitamin D levels were determined at admission to the hospital for all patients in groups I and II and one month after discharge only for patients who presented for reassessment. The optimal level of vitamin
D indicated by the literature is between 25-80 ng/mL, with vitamin insufficiency below 30 ng/mL and vitamin deficiency below 20 ng/mL [17]. The blood concentrations of vitamin D at the time of the fracture were at the lower limit for patients in group I (25 ng/mL±3.52) and well below this value (17 ng/mL±2.28) for those in group II, the difference between the two groups being statistically significant (p <0.001). The values recorded in this study indicate vitamin insufficiency in group I, and vitamin deficiency, in group II, both situations favoring fracture production. One month after discharge the follow-up on patients who returned to control show that during the recovery, they resumed the treatment with bisphosphonates and supplemented calcium and vitamin D. Thus, vitamin D levels, one month after discharge, are in the reference range, for both groups as follows: 37±3.57 ng/mL for group I and respectively 33±3.89 ng/mL for group II. Although both groups present normal vitamin D levels, these concentrations are near the lower limit range. That indicates that the recovery evolved differently, being slower for the group II. Different authors suggest different vitamin D levels for optimal bone metabolism: greater than 30 ng/mL [18] or between 40-60 ng/mL [19]. Patients returned to reassessment were investigated for X-ray radiography which highlighted the callus formation. The dimensions and density of the callus were different in the two groups, which confirms their different recovery. Thus, group I presented fully formed callus and group II presented reduced callus in volume and density. Vitamin D is essential in callus mineralization [20] and probably intervenes also in its formation, therefore, a vitamin deficiency may slow down bone recovery. On the other hand, it is known that although the bisphosphonates delay the remodeling of the callus, they increase the volume by blocking the bone turnover [21, 22]. Thus, the increased volume of the callus in group II may be the result of bisphosphate therapy while the characteristics of the callus in group II may be an indication of a deficient bone remodeling in which recovery was performed in the context of the previous vitamin D deficiency. The obtained data indicate that osteoporotic patients with calcium and vitamin D supplementation show a better recovery. The recommended amounts of calcium and vitamin D for osteoporotic patients over 50 years of age are 1200 mg [23] respectively 32 ng/mL (75 nmol/L) [24]. In osteoporotic patients, post-fracture vitamin D administration is recommended for 5 to 8 weeks with calcium levels checking [25]. Supplementation of osteoporotic treatment with calcium and vitamin D should become mandatory especially for osteoporotic patients who have suffered a fracture, as they have a 2 to 4-fold increased risk of future fracture [8].

Conclusions

Calcium and vitamin D exert a positive influence on the fracture-healing outcome. They are the main nutrients in normal as well as osteoporotic bone remodeling. In the case of any fracture (including FFP) for the surgeon, the stabilization and reduction of the fracture are the main priorities. This may lead to overlook of the administration/supplementation with calcium and vitamin D which may prevent systemic bone loss and reduce the risk of secondary fractures.

The present study revealed the therapeutic potential of calcium and vitamin D supplementation after the fragility fracture in patients with insufficient calcium and vitamin D status.
21. HEGDE, V., JO, J.E., ANDREOPOULOU, P., LANE, J.M., Effect of osteoporosis medication on fracture healing, Osteoporos Int, 27, nr.3, 2016, p.861.
22. SHIN, Y.S., JUNG, H.J., SAVALE, A.P., HAN, S.B., Unusual Excessive Callus Formation in the Intertrochanteric Fracture Treated with Teriparatide., Hip&Pelvis, 26, nr. 1, 2014, p.41.
23. ROSS, A.C., TAYLOR, C.L., YAKTINE, A.L., DELVALLE, H.B., Dietary Reference Intakes for Calcium and Vitamin D, Washington D.C: The national academies press, 2011.
24. NEUPANE, S., KNOHL, S.J., The Institute of Medicine, the Food and Drug Administration, and the calcium conundrum. Public Health Nutr., 17, nr. 8, 2014, p.1865.
25. BISCHOFF-FERRARI, H.A., Optimal serum 25-hydroxyvitamin D levels for multiple health outcomes., Adv Exp Med Biol., 810, 2014; p.500.

Manuscript received: 26.09.2019